Grants for Public housing authorities - Federal

The "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services" grant aims to fund research for developing and testing new care models that effectively combine HIV, addiction, and primary care services to improve health outcomes for individuals at high risk for or living with HIV, Hepatitis, and substance use disorders in the US.

This funding opportunity supports researchers in studying and characterizing genetically modified mice that exhibit early life lethality or reduced viability, contributing to our understanding of gene function and its implications for human health.

The National Heart, Lung, and Blood Institute (NHLBI) intends to publish a Request for Applications (RFA) seeking applications for a multisite clinical trial that will test a screening approach to identify coronary atherosclerosis and test interventions to reduce the progression of coronary atherosclerosis. There will be only one award for this RFA. The planned RFA will utilize the UG3/UH3 activity code with details provided below. The planned RFA will support a Clinical Coordinating Center (CCC) and will run in parallel with a companion RFA for a collaborating Data Coordinating Center (DCC) application.This RFA will accept only an application that is part of a collaborative pair of applications. The pair must include one application to the CCC UG3/UH3 Notice of Funding Opportunity (NOFO) plus one application to the companion DCC U24 NOFO.Both a CCC application and a collaborating DCC application must be submitted on the same due date for consideration by NHLBI. CCC (UG3/UH3) applications submitted without a collaborative DCC (U24) application will be deemed incomplete and will not proceed to review. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The planned RFAs are expected to be published in Summer 2024 with an expected application due date in Fall 2024.

Reissue of RFA-MH-20-401.This Funding Opportunity Announcement (FOA) supports pilot work for subsequent studies testing the effectiveness of strategies to deliver evidence-based mental health services, treatment interventions, and/or preventive interventions (EBPs) in low-resource mental health specialty and non-specialty settings within the United States. The FOA targets settings where EBPs are not currently delivered or delivered with fidelity, such that there are disparities in mental health and related functional outcomes (e.g., employment, educational attainment, stable housing, integration in the community, treatment of comorbid substance use disorders, etc.) for the population(s) served. Implementation strategies should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from EBPs and generate new information about factors integral to achieving equity in mental health outcomes for underserved populations.

This grant provides funding for large-scale, collaborative research projects that explore complex questions related to aging, requiring a multidisciplinary team and integration of various components across institutions.

This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R61/R33) mechanism to provide up to 2 years of R61 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

This grant provides financial support and mentorship for outstanding graduate students in the U.S. who are pursuing a PhD in cancer research, helping them transition to postdoctoral training and independent research careers.

The "IIJA/IRA Bureau of Land Management National Operations Center (NOC) Invasive and Noxious Plant Management Program" grant offers funding between $25,000 to $500,000 to government agencies, educational institutions, and nonprofits for projects aimed at preventing and controlling the spread of invasive and noxious plants on public lands to maintain ecosystem health.

This funding opportunity supports researchers exploring the biological and genetic factors contributing to cancer health disparities among racial and ethnic groups, aiming to generate insights for future studies.

This funding opportunity provides financial support to public and nonprofit organizations that deliver outreach services to homeless and at-risk youth, helping them access essential resources and safer living conditions.

This funding opportunity provides financial support and mentorship for researchers with doctoral degrees to develop their careers in health services research, focusing on improving healthcare quality and equity in the United States.

Notice of Funding Opportunity SummaryNRCS is announcing the availability of Conservation Innovation Grants (CIG) Caribbean Area Program funding to stimulate the development and adoption of innovative conservation approaches and technologies. Applications are accepted from eligible entities (Section C) for projects carried out in the Caribbean Area (Puerto Rico (PR) and the U.S. Virgin Islands (USVI)). A total of up to $500,000 is available for the Caribbean Area CIG competition in FY 2024. All non-Foreign, non-federal entities (NFE) and individuals are invited to apply, with the sole exception of federal agencies. Projects may be between one and three years in duration. The maximum award amount for a single award in FY 2024 is $100,000. For new users of Grants.gov, see Section D. of the full Notice of Funding Opportunity for information about steps required before submitting an application via Grants.gov. Completing all steps required to start an application can take a significant amount of time, plan accordingly.Key DatesApplicants must submit their applications via Grants.gov by 11:59 pm Eastern Time on May 15, 2024 For technical issues with Grants.gov, contact Grants.gov Applicant Support at 1-800-518-4726 or support@grants.gov. Awarding agency staff cannot support applicants regarding Grants.gov accounts. For inquiries specific to the content of the NFO requirements, contact the federal awarding agency contact (section G of this NFO). Please limit questions to those regarding specific information contained in this NFO (such as dates, page numbers, clarification of discrepancies, etc.). Questions related to eligibility, or the merits of a specific proposal will not be addressed.A webinar for CIG applicants is scheduled for April 9, 2024 at 9 a.m. Atlantic Standard Time. Information on how to participate in the webinar will be posted to the HYPERLINK website. Applicants are encouraged to visit the Caribbean Area CIG website to learn more about the CIG program.The agency anticipates making selections by June 30, 2024 and expects to execute awards by July 30, 2024. These dates are estimates and are subject to change.

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) that were developed for the treatment of type 2 diabetes (T2D) have significant protective effects for cardiac and renal diseases for people with and without diabetes. However, SGLT2i are not currently approved for individuals with type 1 diabetes (T1D) and there is an increased risk of diabetic ketoacidosis (DKA) for this population. Despite this concern, these drugs are increasingly being prescribed off-label for people with T1D. Continuous ketone monitoring (CKM) is a rapidly evolving technology that could be utilized clinically to prevent DKA by an early warning of elevations in ketone levels.The purpose of this NOFO is to solicit applications for studies that will develop and test risk mitigation strategies that involve the clinical integration of CKM for the safe use of SGLT2i for people living with T1D so that they may benefit from the cardiac and renal protection and glucose-lowering effects of this drug class. The NOFO will support short-term, clinical trials to gain and disseminate knowledge on safety and glucose control with CKM and SGLT2i use.Possible topics include testing optimal insulin delivery in open and closed loop systems or multiple daily injections and developing clinical protocols to control or ameliorate elevated ketone levels in individuals with T1D who are receiving adjunct therapy with SGLT2i.

This funding opportunity supports innovative research on how substance use disorders affect HIV infection and latency in the brain, encouraging collaboration among researchers in HIV, neuroscience, and addiction.

This grant provides funding for research on how climate change affects cancer risks, prevention, treatment, and survivorship, particularly focusing on vulnerable populations and health disparities.

FDA announces the availability of fiscal year (FY) 2024 funds to support one or more projects to 1) collect antimicrobial use data from diverse animal sectors, including domestic livestock, poultry, companion animals (dogs, cats, and horses), and minor species (e.g., fish, sheep, goats, etc.) and 2) contribute to the development of data collection frameworks, including providing data and expertise as resources and a public-private partnership frameworks are established.This grant will support the continued advancement of FDA's initiatives to support antimicrobial stewardship in veterinary settings. It will also support the National Action Plan objectives to engage the animal health community and relevant stakeholders to advance strategies intended to improve understanding of antimicrobial use and foster antimicrobial stewardship in animal agriculture.

This funding opportunity provides financial support to organizations that will assist Botswana's Ministry of Health in implementing national HIV policies and improving care and mental health services for children and adolescents living with HIV.

This funding opportunity supports collaborative projects between academic institutions and industry to develop innovative bioengineering solutions that address significant biomedical challenges and improve medical practices.

The Agency for Healthcare Research and Quality's (AHRQ) mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. AHRQ's Center for Quality Improvement and Patient Safety (CQuIPS) works to ensure patient safety in multiple settings with recent efforts to increase the development of processes including measures, metrics, tools and practices to increase patient safety in the ambulatory care setting and in long-term care facilities.

This funding supports institutions in developing training programs for predoctoral and postdoctoral researchers in biomedical and clinical fields, with a focus on enhancing diversity and preparing trainees for successful research careers.